CLOs on the Move

Bellicum

www.bellicum.com

 
Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.bellicum.com
  • 2130 West Holcombe Boulevard Suite 800
    Houston, TX USA 77030
  • Phone: 832.384.1100

Executives

Name Title Contact Details
Anavelys Ortiz-Suarez
 Associate General Counsel Profile
Anavelys Ortiz--Suarez
 Associate General Counsel Profile

Similar Companies

Meitheal Pharmaceuticals

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products. Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy. Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.

Nutrishare Inc

Nutrishare Inc is a Elk Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantom Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.

Tensentric

Tensentric has one focus: the design and development of medical devices. This narrow focus and expertise is tailored to meet the specific needs of each of our clients and lets us design as efficiently as possible. Tensentric is ISO13485:2003 certif...